Presented Poster at ESMO Asia Congress 2019

AroCell have previously announced that the results from the PROMIX breast cancer study have been presented at ESMO. The poster that was presented is titles “Tumour Response to Neoadjuvant Chemotherapy in Breast Cancer: Routine Pathologic Markers Improve the Predictive Power of a Cell-Loss Metric Based on Release of Thymidine Kinase 1 (sTK1) into Blood” and can be found here below.